CRISM Therapeutics Corporation (AIM:CRTX)

Market Cap	5.83M -24.1%
Revenue (ttm)	231.00K +824.0%
Net Income	-1.90M
EPS	-0.05
Shares Out	54.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	10.23
Previous Close	10.50
Day's Range	10.00 - 11.50
52-Week Range	8.00 - 18.50
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2026

About CRISM Therapeutics

CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs. Its lead product is ChemoSeed, an implantable biodegradable drug delivery technology for the delivery of chemotherapy directly into cancer tissues. The company also offers formulation and consultancy services. The company was formerly known as Amur Minerals Corporation and changed its name to CRISM Therapeutics Corporation in May 2024. CRISM Therapeutics Corporati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 4
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CRTX

Financial Performance

In 2025, CRISM Therapeutics's revenue was 231,000, an increase of 824.00% compared to the previous year's 25,000. Losses were -1.90 million, 213.5% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 6, 2026

Data Sources Report a data error